Key result
SGLT-2 inhibitors and some GLP-1 agonists are associated with improved heart failure outcomes, whereas thiazolidinediones and certain DPP-4 inhibitors have been shown to increase this risk.
Why the study?
What are the effects of different classes of type 2 diabetes medications on heart failure outcomes?
What are the effects of different classes of type 2 diabetes medications on heart failure outcomes?
This review highlights that while SGLT-2 inhibitors and some GLP-1 agonists improve heart failure outcomes in patients with type 2 diabetes, thiazolidinediones and certain DPP-4 inhibitors may increase heart failure risk.
Supports class-specific HF effects in T2D; hypothesis-generating and should not yet change practice.
Heart failure is a common complication associated with type 2 diabetes (T2DM) and the presence of both carries a poorer prognosis. Recent cardiovascular outcome trials have drawn attention to the contrasting effects of the different classes of agents used in the management of T2DM on heart failure outcomes. While SGLT‐2 inhibitors and some GLP‐1 agonists are associated with improved outcomes with regard to heart failure, thiazolidinediones and certain DPP‐4 inhibitors have been shown to increase this risk. In this review article, we will review each of these drug classes and discuss the evidence, if any, for their use in heart failure.
No takes yet. Share an insight, caveat, or question.
Llano et al. (2018) conducted a review in Type 2 diabetes and heart failure. SGLT-2 inhibitors, GLP-1 agonists, thiazolidinediones, DPP-4 inhibitors was evaluated. SGLT-2 inhibitors and some GLP-1 agonists are associated with improved heart failure outcomes, whereas thiazolidinediones and certain DPP-4 inhibitors have been shown to increase this risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: